SC
SCNI.US Scinai Immunotherapeutics Ltd
- Market cap
- USD 1.05M
- P/E
- 0.1x
- P/B
- 0.21x
- ROE
- -5.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SCNI.US undervalued?
Graham numberThe Graham number of Scinai Immunotherapeutics Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Scinai Immunotherapeutics Ltd fundamental analysis
No fundamental analysis for Scinai Immunotherapeutics Ltd yet.
Scinai Immunotherapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract develo…
Full company profileScinai Immunotherapeutics Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Scinai Immunotherapeutics Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 658K | 1.31M | 3.75M |
| Gross Profit | - | - | - | - | -709K | -748K | -560K | -513K | -580K | -2.65M | -3.99M |
| Operating Income | -3.09M | -6.80M | -20.6M | -22.7M | -19.8M | -10.8M | -11.1M | -9.71M | -8.64M | -7.54M | -8.79M |
| EBITDA | -2.93M | -6.67M | -20.5M | -22.2M | -19.1M | -10.3M | -5.23M | -2.19M | -6.99M | -6.53M | -6.70M |
| Net Income | -2.38M | -9.93M | -23.5M | -31.6M | -1.30M | -12.4M | -5.80M | -6.50M | 4.80M | -8.31M | -583K |
| EPS | -706 | -1,976 | -3,590 | -3,872 | -647,712 | -4,125,540 | -123,319 | -67,010 | 59 | -36 | -2.42 |
| Balance Sheet | |||||||||||
| Total Assets | 7.82M | 23.5M | 28.3M | 33.5M | 17.7M | 32.0M | 27.1M | 17.5M | 13.4M | 11.6M | 15.7M |
| Total Liabilities | 1.17M | 7.31M | 36.6M | 52.4M | 22.2M | 31.1M | 28.8M | 22.0M | 3.47M | 3.52M | 4.98M |
| Shareholders' Equity | 6.65M | 16.2M | -8.35M | -18.8M | -4.54M | 982K | -1.76M | -4.57M | 9.98M | 8.10M | 10.7M |
| Cash & Short-term Investments | 6.57M | 20.5M | 20.3M | 21.0M | 2.93M | 17.4M | 14.1M | 4.87M | 1.96M | 1.66M | 1.71M |
| Total Debt | - | - | 25.2M | 38.0M | 20.9M | 29.2M | 21.5M | 20.6M | 2.09M | 2.27M | 3.39M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.51M | -2.89M | -15.3M | -22.3M | -21.1M | -7.43M | -7.27M | -9.38M | -6.34M | -6.03M | -7.77M |
| Capital Expenditure | 5.19K | 1.30M | 6.35M | 2.15M | 1.78M | 139K | 836K | 637K | 12.0K | 24.0K | 308K |
| Free Cash Flow | -2.51M | -4.18M | -21.6M | -24.5M | -22.9M | -7.57M | -8.10M | -10.0M | -6.35M | -6.06M | -8.07M |
| Ratios | |||||||||||
| ROE | -35.9% | -61.4% | - | - | - | -1,260.3% | - | - | 48.1% | -102.5% | -5.4% |
| ROA | -30.5% | -42.3% | -82.9% | -94.3% | -7.3% | -38.6% | -21.4% | -37.2% | 35.7% | -71.5% | -3.7% |
| Net Profit Margin | - | - | - | - | - | - | - | - | 728.9% | -633.6% | -15.5% |
| Debt to Equity | - | - | - | - | - | 29.77x | - | - | 0.21x | 0.28x | 0.32x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Scinai Immunotherapeutics Ltd dividends
Scinai Immunotherapeutics Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Aug 21, 2026.
Who owns Scinai Immunotherapeutics Ltd
- Insiders 3.07%
- Institutions 2.12%
- Public & others 94.81%
- Shares outstanding 2.63M
- Free float 1.27M
Top funds holding SCNI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® Ptf Dev Wld exUS ETF | 2.00 | 0.00% | 0.00% | Jul 2026 |
Top institutions holding SCNI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 35.9K | 0.34% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 19.5K | 0.19% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 16.8K | 0.16% | -30.27% | Jun 2026 |
| StoneX Group Inc | 13.1K | 0.12% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 12.1K | 0.11% | 0.00% | Jun 2026 |
| CapTrust Financial Advisors | 12.0K | 0.11% | 0.00% | Jun 2026 |
| UBS Group AG | 3.96K | 0.04% | +330.36% | Jun 2026 |
| Rhumbline Advisers | 1.35K | 0.01% | -0.15% | Sep 2026 |
| Royal Bank of Canada | 815.00 | 0.01% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 58.00 | 0.00% | 0.00% | Jun 2026 |
Scinai Immunotherapeutics Ltd company profile
- Company name
- Scinai Immunotherapeutics Ltd
- Ticker
- SCNI.US
- Exchange
- USA Stocks
- Listed since
- May 12, 2015
- Sector
- Healthcare
- Industry
- Semiconductors & Semiconductor Equipment
- Employees
- 45
- Fiscal year end
- December
- Address
- Jerusalem BioPark, Jerusalem, Israel
- Phone
- 972 8 930 2529
- Website
- scinai.com
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
Scinai Immunotherapeutics Ltd management
7- Mr. Amir Reichman M.B.A., M.Sc.CEO & Director · born 1976
- Mr. Uri Ben-Or CPA, M.B.A.Chief Financial Officer · born 1970
- Mr. Elad Mark B.Sc., Eng., M.B.A.Chief Operating Officer · born 1983
- Gal RonHead of HR
- Merav KamenskyHead of Quality Control & GMP Analytics
- Dr. Naama Adi HenHead of Quality Asurance
- Mr. Eran KuratzHead of Supply Chain & Business Process Administration